DSM-Firmenich AG/ADR (DSFIR NA) Stock Price Quote, News &…

Summary

DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.

Website

www.dsm-firmenich.com

Location

Kaiseraugst, NY, CH

Phone41 61 815 17 26

Employees28,550

CEODimitri de Vreeze

Sector

Industrials

Industry

Professional Services

IPO DateMay 9, 2023

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… . 40 --- The market for supplying enzymes is fragmented. There is competition from large industrial enzyme companies, such as Novozymes and DuPont, as well as subsidiaries of larger contract research/CMOs, such as DSM-Firmenich AG, Cambrex Corporation, Lonza Group, WuXi STA and Almac Group Ltd. Some fermentation pathway design companies, like Ginkgo Bioworks, whose traditional focus has been to design microorganisms that express small molecule …
CODEXIS, INC.DSM-Firmenich AG/ADR·10-Q - Quarterly report Q3·Q3 26·12 Nov
… During his tenure, he advised multi-national companies, financial institutions and family-controlled businesses on major transactions and corporate situations. Client experience included advising Burberry Group plc, DSM-Firmenich AG, First Eastern Investment Group, Kering SA, Melco Resorts & Entertainment Limited, INDITEX (Industria de Diseño Textil, S.A), New World Development Company Limited, Pacific Century Group and Prudential plc. Mr. Lo re …
AParadise III Acquisition Corp.DSM-Firmenich AG/ADR·S-1 - REGISTRATION STATEMENT·Q4 26·6 Nov
… / 2028E sales (1)–(4) Growth-adjusted EV / 2029E sales (1)–(5) Idorsia Idorsia IFF Indivior 8.3x 7.0x 70.9x (4%) 92.7x (4%) Brains Bio (cal.) Lonza Indivior IFF 6.2x 4.2x 56.3x (6%) 73.5x (4%) Lonza Brains Bio (cal.) DSM-Firmenich Alcon 4.7x 3.5x 52.2x (5%) 45.0x (6%) Indivior Indivior Alcon Siegfried 3.6x 3.5x 48.7x (6%) 40.1x (6%) Jazz Pharma Jazz Pharma Santen Idorsia 3.5x 3.1x 45.5x (4%) 38.3x (18%) IFF IFF Lonza Lonza 3.2x 3.1x 39.5x (12%) …
Armada Acquisition Corp. IIIDSM-Firmenich AG/ADR·425 - Form 425 - Business combination communication·Q1 27·5 Nov
… / 2028E sales (1)–(4) Growth-adjusted EV / 2029E sales (1)–(5) Idorsia Idorsia IFF Indivior 8.3x 7.0x 70.9x (4%) 92.7x (4%) Brains Bio (cal.) Lonza Indivior IFF 6.2x 4.2x 56.3x (6%) 73.5x (4%) Lonza Brains Bio (cal.) DSM-Firmenich Alcon 4.7x 3.5x 52.2x (5%) 45.0x (6%) Indivior Indivior Alcon Siegfried 3.6x 3.5x 48.7x (6%) 40.1x (6%) Jazz Pharma Jazz Pharma Santen Idorsia 3.5x 3.1x 45.5x (4%) 38.3x (18%) IFF IFF Lonza Lonza 3.2x 3.1x 39.5x (12%) …
Armada Acquisition Corp. IIIDSM-Firmenich AG/ADR·EX-99.2 - 8-K - Entry into a Material Definitive Agreement·Q1 27·5 Nov
… “Company”) appointed Frits Dirk van Paasschen, 65, to the Board, effective immediately. Mr. van Paasschen brings extensive board experience across consumer, retail and technology businesses. He serves on the boards of DSM-Firmenich, Amadeus IT Group and Williams-Sonoma, and until recently served on the board of J.Crew. Mr. van Paasschen spent more than a decade as a Fortune 500 CEO at global consumer and lifestyle brands, including Starwood Hote …
PVH CORP. /DE/DSM-Firmenich AG/ADR·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 27·2 Nov
… strengthen our Board and help position the company for long-term profitable growth.” Mr. van Paasschen currently serves on the boards of leading companies across the consumer, retail and technology sectors, including DSM-Firmenich, Amadeus IT Group, and Williams-Sonoma. Until recently, he also served on the board of J.Crew. “Frits brings significant public and private company board experience and more than a decade as a global CEO with a proven …
PVH CORP. /DE/DSM-Firmenich AG/ADR·EX-99.1 - 8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 27·2 Nov

Key Stats

Trading

Px/Chg 1D$97.38 / +1.27%

Prev Close$95.30

% of 52Wk H98.97%

Avg Volume1.02M

Beta0.22

Mkt Cap24.04B

FD Mkt Cap23.64B

Float

Shrs Out/Float246.87M / 217.04M

Short Float0.00%

Days to Cover0.00

Stock Repurchased$1.18B

Current Valuation

EV27.71B

EV/EBITDA12.52

EV/Sales2.13

P/B1.32

P/S1.85

FCF Yield3.11%

ROE-5.93%

ROA-3.68%

Current Ratio1.59

Dividend

Cash$2.50

Yield3.86%

Yield (TTM)3.86%

Estimates

P/E33.48

Est P/E0.00

Est EPS1.67

Est PEG0.00

Valuation

Metric	5Yr Avg	Mar '24	Mar '25	Oct '26
PRICE-BASED RATIOS
Price / Earnings	31.48	11.50	97.90	-14.98
Price / Sales	4.56	2.31	1.91	9.44
Price / Book Value	1.16	1.07	1.09	1.31
Price / Free Cash Flow	30.20	34.62	24.14	31.86
ENTERPRISE VALUE METRICS
Enterprise Value	27,327.2	27,115.3	27,364.5	27,501.9
Enterprise Value / Sales	5.20	2.55	2.14	10.90
Enterprise Value / EBITDA	47.63	32.99	48.78	61.12
Enterprise Value / EBIT	57.93	-55.91	48.78	180.93

Financials

Full Financials

Millions EUR	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	-5.7%	11,444.0	8,390.0	10,627.0	12,799.0	9,034.0
Gross Income	-4.2%	4,187.0	2,781.0	2,611.0	4,245.0	3,530.0
EBITDA	27.6%	1,454.0	1,313.0	822.0	561.0	3,851.0
EBIT	-4.6%	859.0	661.0	-485.0	561.0	711.0
Net Income	—	872.0	460.0	2,137.0	250.0	-1,081.0
EPS (Diluted)	—	5.04	2.61	-2.82	0.94	-4.17
BALANCE SHEET
Cash & ST Inv	-1.8%	2,050.0	2,880.0	2,563.0	2,717.0	1,903.0
Total Assets	16.3%	16,020.0	17,403.0	34,270.0	33,747.0	29,345.0
Total Liabilities	13.3%	6,623.0	6,558.0	11,200.0	11,050.0	10,922.0
Total Shareholder Equity	18.3%	9,318.0	10,743.0	22,908.0	22,511.0	18,244.0
CASH FLOW
Net Operating Cash Flow	-69%	1,427.0	923.0	1,265.0	1,778.0	1,388.0
Cap Ex	15.3%	-433.0	-644.0	-555.0	-764.0	-764.0
Free Cash Flow	-11%	994.0	279.0	710.0	1,014.0	624.0

Enterprise Value Bridge

Millions EUR		13 Nov '26
Price (As of 13 Nov '26)		105.25
Basic Shares		246.87
Market Cap		25,983.1
Diluted Shares		250.20
Fully Diluted Shares Outstanding		250.20
Fully Diluted Market Cap		26,333.6
+Consolidated Debt		6,765.0
−In-the-Money Convertible Debt		—
+Capital Leases		-
+Operating Leases		—
−Cash & Equivalents		-2,261.0
−Short-term Investments		-47.0
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		148.0
+Pension Liabilities		—
Enterprise Value		30,635.1

Related companies